[Serum cytokine profiling of prostate cancer and benign prostatic hyperplasia using recombinant antibody microarray].
OBJECTIVE
To identify the differential expressions of serum cytokines between prostate cancer (PCa) and benign prostatic hyperplasia (BPH), and provide proteomic evidence for the early diagnosis of PCa.


METHODS
We used human cytokine array to determine the profiles of the serum cytokines obtained from 6 PCa and 6 BPH patients with the PSA level within the grey scale of 4 - 10 ng/ml.


RESULTS
We identified 19 differentially expressed cytokines in the PCa patients, 16 obviously up-regulated, including IL-3, IL-6 and IL-16, and 3 markedly down-regulated, which were Fas/TNFRSF6, TRALR-3 and IGFBP-6. Most of them were involved in such cellular bioprocesses as transcription, proliferation, signal transduction, and apoptosis.


CONCLUSIONS
The cytokine antibody assay permits simultaneous measurement of multiple markers in a small volume of serum, and can identify a panel of key cytokines related to the malignant biological behavior of cancer cells. And it helps to find the biomarkers for the early diagnosis, efficacy assessment and prognosis of prostate cancer.
Zhang
Lei
L
Department of Urology, PLA General Hospital, Beijing 100853, China. zhanglei301@yahoo.com
Sun
Sheng-Kun
SK
Shi
Li-Xin
LX
Zhang
Xu
X
D000368:Aged; D006801:Humans; D019410:Interleukin-16 / Q000097:blood; D007377:Interleukin-3 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D040901:Proteomics
D019410:Interleukin-16; D007377:Interleukin-3; D015850:Interleukin-6